| Metric | Value ($ M) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 102.22 | 11.8% | 1.4% |
| Total Income | 102.22 | 11.8% | 1.4% |
| Expenditure | 115.83 | 2.6% | 4.5% |
| PBT | -14.07 | 2658.8% | 4790.0% |
| Net Profit | -14.22 | 1655.6% | 7800.0% |
| OPM | -13.31% | 10.73pp | 6.40pp |
| NPM | -13.91% | 13.22pp | 13.74pp |
| EPS | -0.28 | 1300.0% |
Immunocore Reports Q3 2026 Financial Results and Provides Business Update
06 Nov 2026 · 1h ago
Summary
Immunocore Holdings plc announced its financial results for the third quarter ended September 30, 2026. Total net product revenue for KIMMTRAK was $102.2 million in Q3 2026, with underlying growth estimated at 10% year-over-year after normalization. For the first nine months of 2026, net sales reached $324.8 million, up from $295.5 million in the prior year. The company reported a net loss of $14.2 million for the quarter, compared to a net loss of $0.2 million in Q3 2025. Key business updates include the completion of enrollment for the Phase 3 TEBE-AM trial and the dosing of the first patient in the Phase 1 trial for its type 1 diabetes candidate, IMC-S118AI.
Key Highlights
- 1
KIMMTRAK net revenues were $102.2 million in Q3 2026, a slight decrease from $103.7 million in Q3 2025, but underlying revenue growth was approximately 10% when normalizing for specific US-related factors.
- 2
Net sales of KIMMTRAK for the first nine months of 2026 reached $324.8 million, an increase from $295.5 million in the same period of 2025, representing continued growth across regions.
- 3
The Phase 3 TEBE-AM trial for advanced cutaneous melanoma completed target enrollment of 540 patients, with topline overall survival data expected in the second quarter of 2027.
- 4
The first patient with type 1 diabetes was dosed in the Phase 1 trial of IMC-S118AI, the Company's first tissue-specific autoimmune candidate.
- 5
Cash, cash equivalents, and marketable securities stood at $901 million as of September 30, 2026, providing a strong liquidity position.
- 6
Net loss for Q3 2026 was $14.2 million ($0.28 loss per share), compared to a net loss of $0.2 million ($0.00 loss per share) for Q3 2025.
Management Comments
Bahija Jallal
Nearly five years after launch, KIMMTRAK remains the proven standard of care in HLA-A*02:01+ metastatic uveal melanoma. With TEBE-AM fully enrolled and data expected in the second quarter of 2027, we are advancing our mission to bring this therapy to even more patients. Recently, our platform delivered two significant firsts: what we believe is the first data demonstrating clinical activity and a manageable safety profile with the combination of two T cell engagers in a solid tumor, and the first patient dosed in our tissue-specific autoimmune program for type 1 diabetes.
Informational and educational content only. Not investment advice.